Instructions for Viferon (Interferon alfa-2b) 36000 МЕ
English product name
Viferon
Release Form
gel d/external and local approx. 36 000 IU/1 g: 12 g tube
Description
Gel for outdoor and local use in the form of a uniform, opaque, gel-like mass of white color with a greyish tint.
1g
human recombinant interferon alpha-2b 36,000 IU
Auxiliary substances: α-tocopherol acetate - 55 mg, benzoic acid - 1.28 mg, tetraborate sodium decahydrate - 1.8 mg, methionine - 1.2 mg, citric acid monohydrate - 1 mg, sodium chloride - 4 mg, whey-human albumin solution 10% - 20 mg, glycerol (glycerine distilled) - 20 mg, sodium carmellose - 20 mg, ethanol 95% - 55 mg, water purified - up to 1 g.
12 g - aluminium tubes (1) - cardboard packs.
ATC codes
L03AB05 Interferon alfa-2b
Clinical-pharmacological groups / Group affiliation
Antiviral preparation for external use
Active substance
human recombinant interferon alpha-2b
Pharmaco-therapeutic group Viferon
MIBP-Cytokin
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature of 2° to 8°C.
Best before date
The shelf life is one year. Do not use the drug after the expiry date.
The opened tube is stored in the refrigerator for a maximum of two months.
Pharmacological effect Viferon
Interferon alpha-2b human recombinant has immunomodulatory, antiviral and antiproliferative properties. It suppresses the replication of RNA and DNA viruses. The immunomodulatory properties of interferon, such as the increase in the phagocytic activity of macrophages, and the increase in the specific cytotoxicity of lymphocytes to target cells, cause its mediated antibacterial activity.
- Nosology Viferon (ICD codes)
- A60
- Anogenital herpetic virus infection [herpes simplex]
- B00
- Infections caused by herpes simplex virus [herpes simplex]
- B02
- Shingles [herpes zoster]
- J04.2
- Acute laryngotracheitis
- J06.9
- Acute upper respiratory tract infection unspecified
- J10
- Influenza caused by an identified seasonal influenza virus
- J20
- Acute bronchitis
- J37.1
- Chronic laryngotracheitis
- J42
- Chronic bronchitis unspecified
- N72
- Inflammatory disease of the cervix (incl. cervicite, endocervicite, exocervicite)
Testimony
- as part of a comprehensive treatment of ARVI,
- including influenza,
- frequent and long-term ARVI, including complicated by bacterial infection;
- ARVI prevention, including influenza;
- as part of the complex therapy of recurrent stenosylating laryngotracheobronchite;
- Prevention of recurrent stenosylating laryngotracheobronchite;
- as part of the complex therapy of acute and exacerbation of chronic recurrent herpetic infection of the skin and mucous
- membranes,
- including urogenital form of herpetic infection;
- as part of the complex therapy of herpetic cervicite.
